REMEDIES FOR PEMPHIGUS CONTAINING ANTI FAS LIGAND ANTIBODIES

摘要

The present invention refers to the use of FasL antagonists, e.g. of humanizedantibodies directed against humanFas ligands (also named CD95L or Apo1L and hereinafter abbreviated as FasL)for the prevention and/or treatment of skindiseases associated with keratinocytes acantholysis, particularly for theprevention and/or treatment of pemphigus.